Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.
Hodgkin lymphoma statistics
New cases of Hodgkin lymphoma, 2014-2016 average, UK
Deaths from Hodgkin lymphoma, 2016, UK
Survive Hodgkin lymphoma for 10 or more years, 2010-11, England and Wales
Hodgkin lymphoma cases are preventable, UK, 2015
- There are around 2,100 new hodgkin lymphoma cases in the UK every year, that's nearly 6 every day (2014-2016).
- Hodgkin lymphoma is not among the 20 most common cancers in the UK, accounting for less than 1% of all new cancer cases (2016).
- In females in the UK, hodgkin lymphoma is not among the 20 most common cancers, with around 880 new cases in 2016.
- In males in the UK, hodgkin lymphoma is the 19th most common cancer, with around 1,200 new cases in 2016.
- Incidence rates for Hodgkin lymphoma in the UK are highest in people aged 80 to 84 (2013-2015).
- Since the early 1990s, Hodgkin lymphoma incidence rates have increased by more than a third (36%) in the UK. Rates in females have increased by around two-fifths (41%) and rates in males have increased by a third (33%).
- Over the last decade, Hodgkin lymphoma incidence rates have increased by more than a fifth (22%) in the UK. Rates in females have increased by around a fifth (21%), and rates in males have increased by more than a fifth (22%).
- Most Hodgkin lymphoma cases are diagnosed at an early stage.
- Incidence rates for Hodgkin lymphoma are projected to rise by 5% in the UK between 2014 and 2035, to 4 cases per 100,000 people by 2035.
- Hodgkin lymphoma in England is more common in males living in the most deprived areas. There is no association for females.
- Hodgkin lymphoma is as common in White, Asian and Black people.
- An estimated 21,600 people who had previously been diagnosed with Hodgkin lymphoma were alive in the UK at the end of 2010.
- There are around 330 hodgkin lymphoma deaths in the UK every year, that's around 1 every day (2014-2016).
- Hodgkin lymphoma is not among the 20 most common causes of cancer death in the UK, accounting for less than 1% of all cancer deaths (2016).
- In males in the UK, hodgkin lymphoma is not among the 20 most common causes of cancer death, with around 180 deaths in 2016.
- In females in the UK, hodgkin lymphoma is not among the 20 most common causes of cancer death, with around 130 deaths in 2016.
- Mortality rates for Hodgkin lymphoma in the UK are highest in people aged 80 to 84 (2014-2016).
- Since the early 1970s, Hodgkin lymphoma mortality rates have decreased by around seven-tenths (71%) in the UK. Rates in males have decreased by around seven-tenths (71%), and rates in females have decreased by seven-tenths (70%).
- Over the last decade, Hodgkin lymphoma mortality rates have remained stable in the UK. Rates in males have remained stable, and rates in females have remained stable.
- Mortality rates for Hodgkin lymphoma are projected to fall by 26% in the UK between 2014 and 2035, to 1 deaths per 100,000 people by 2035.
- Hodgkin lymphoma deaths in England are more common in males living in the most deprived areas. There is no association for females.
- 8 in 10 (80%) people diagnosed with Hodgkin lymphoma in England and Wales survive their disease for ten years or more (2010-11).
- Almost 9 in 10 (85%) people diagnosed with Hodgkin lymphoma in England and Wales survive their disease for five years or more (2010-11).
- Around 9 in 10 (91%) people diagnosed with Hodgkin lymphoma in England and Wales survive their disease for one year or more (2010-11).
- Hodgkin lymphoma survival is higher in women than men.
- Hodgkin lymphoma survival in England is higher for people diagnosed aged under 40 years old (2009-2013).
- 95% of people in England diagnosed with Hodgkin lymphoma aged 15-39 survive their disease for five years or more, compared with more than a quarter of people diagnosed aged 80 and over (2009-2013).
- Hodgkin lymphoma survival is improving and has increased in the last 40 years in the UK.
- In the 1970s, almost half of people diagnosed with Hodgkin lymphoma survived their disease beyond ten years, now it's 8 in 10.
- Five-year relative survival for Hodgkin lymphoma in men is similar to the European average in England, Wales, Scotland and Northern Ireland.
- Five-year relative survival for Hodgkin lymphoma in women is below the European average in England but similar to the European average in Wales and Scotland.
- A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- 1 in 360 UK males and 1 in 505 UK females will be diagnosed with Hodgkin lymphoma in their lifetime.
- 40% of Hodgkin lymphoma cases in the UK are preventable.
- 40% of Hodgkin lymphoma cases in the UK are caused by infections.
- 'Two-week wait' is the most common route to diagnosing Hodgkin lymphoma.
- ‘Two-week wait’ and ’31-day wait’ standards are met by all countries, and ‘62-day wait’ is not met by any country for haematological cancers.
The latest statistics available for Hodgkin lymphoma in the UK are; incidence 2015, mortality 2014 and survival 2010-2011 (all ages combined) and 2009-2013 (by age).
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Overall, the evidence on Hodgkin lymphoma risk factors is limited, mainly because of this cancer's relative rarity and diversity. Studies which group together different morphological subtypes of Hodgkin lymphoma may be confounded if those subtypes have differing aetiologies.
Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2012-2013.
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Hodgkin lymphoma is part of the group 'Haematological cancers' for cancer waiting times data. Codes vary per country but broadly include: Hodgkin lymphoma, follicular and non-follicular lymphoma, mature T/NK-cell lymphoma, other and unspecified types of NHL, other and unspecified types of T/NK-cell lymphoma, malignant immunoproliferative diseases, myeloma, lymphoid, myeloid and monocytic leukaemia, some other leukaemia of specific or unspecified cell type, and other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.
When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or
We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.